Search Clinical Trials
Before medications are approved by the U.S. Food and Drug Administration (FDA) or before certain therapy methods are widely accepted as effective, they are tested on people who volunteer to participate in a clinical trial.
Organizations across the country are looking for people like you to take part in their research studies. The list of studies below have been selected from ClinicalTrials.gov based on their inclusion of one or more of the following terms: anxiety disorders, depression, OCD, PTSD, and bipolar disorder.
The Anxiety and Depression Association of America (ADAA) is supportive of research that is conducted through clinical trials. Participating in research can potentially help change the mental health outcomes for you and others who suffer anxiety, depression, and related disorders. You may learn about new interventions/treatments that are being considered.
Read this ADAA blog about things to know and questions to ask before committing to a clinical trial.
This website page is brought to you in partnership with ResearchMatch.
Sponsor Condition of Interest |
---|
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, a1
National Institute of Mental Health (NIMH)
Bipolar Disorder
Major Depression
Migraine
Background:
Mood disorders, such as bipolar disorder, can have serious effects on a person s life.
People with bipolar disorder are more likely to have heart disease and abuse substances.
In this natural history study, researchers would like to learn more about the connection
between exercise and1 expand
Background: Mood disorders, such as bipolar disorder, can have serious effects on a person s life. People with bipolar disorder are more likely to have heart disease and abuse substances. In this natural history study, researchers would like to learn more about the connection between exercise and mental health in people with and without mood disorders. Objective: To better understand relationships among physical activity, sleep, and mental health. Eligibility: People aged 12 to 60 years with a history of a mood disorder. Healthy spouses and relatives with no mood disorders are also needed. Design: Participants will be in the study up to 2 years. For up to 20 days in a row, at 4 times during the study, participants will: Complete an electronic diary on their smartphone. Participants will answer questions about their mood, health, sleep, and daily activities. Wear an activity monitor, like a wristwatch, that records how much they move. Wear a light sensor, as a necklace, to record the amount of light in their environment. Some participants will do additional tests. Twice during the study, for 3 days in a row, they will: Wear monitors to record their temperature, heart rate, and sleep. Provide saliva samples. Complete cognitive tasks on their smartphone. Participants will visit the NIH clinic 2 times. They will have a physical exam, with blood and urine tests. They will wear a heart monitor. They will ride a stationary bike for 30 minutes. They may have an imaging scan. Some participants will stay overnight. They will go to sleep wearing a cap to measure their brain activity. Type: Observational Start Date: Nov 2023 |
Using a Mentoring Afterschool Program to Improve Adolescent Mental Health and Physical Activity: A1
University of Minnesota
Depression
Coming out of the COVID-19 pandemic many youth are experiencing declines in physical
activity and worsening mental health (e.g., depression symptoms). These declines are
exacerbated among underserved youth who experience greater barriers to health services
and exposure to life stressors that put th1 expand
Coming out of the COVID-19 pandemic many youth are experiencing declines in physical activity and worsening mental health (e.g., depression symptoms). These declines are exacerbated among underserved youth who experience greater barriers to health services and exposure to life stressors that put them at increased risk for impaired mental, emotional, and behavioral health. School-based afterschool programming is an important strategy to reach this population of youth and provides intervention at a time when youth are likely to otherwise be in environments not supportive of health. Further participation in extracurricular activities has been shown to be a protective factor for youth mental health. However, consistent with the Behavioral Theory of Depression, youth who are currently inactive and who have depression symptoms are unlikely to participate in afterschool programming on their own and likely require heightened positive reinforcement when they do attend to encourage retention. Given the high prevalence of youth who experience symptoms of depression and resource and staffing challenges faced by many schools, the level of support needed to engage students to consistently participate and benefit from afterschool programming is often beyond the capacity of school-based afterschool programs. In partnership with a local afterschool program for middle school students in a low resource community, we developed an augmented version of the current afterschool program in which college students are trained to mentor and assist in the afterschool program, expanding the capacity of the afterschool program to engage students. The mentoring intervention uses behavioral activation principles to help youth connect their behaviors with their mood and support youth to engage in behaviors that improve their mood, including physical activity. The main purpose of this study is to pilot the feasibility of the newly developed intervention. Type: Interventional Start Date: Sep 2024 |
Pilot Trial of Group Exposure Workshops for Socially Anxious Undergraduates
University of Colorado, Boulder
Social Anxiety Disorder
Public Speaking Fear
Public Speaking Anxiety
Social Fear
The purpose of the study is to investigate the effects of four versions of a workshop for
social anxiety and public speaking stress. All participants are current University of
Colorado Boulder undergraduate students. Participation in this research study lasts for
approximately 8 weeks, and includes1 expand
The purpose of the study is to investigate the effects of four versions of a workshop for social anxiety and public speaking stress. All participants are current University of Colorado Boulder undergraduate students. Participation in this research study lasts for approximately 8 weeks, and includes a pre-workshop questionnaire, 3 weekly workshop sessions (ranging from 2 to 3 hours each, including a 5-minute post-session questionnaire), a post-workshop questionnaire, and a 1-month follow-up questionnaire. Type: Interventional Start Date: Jun 2024 |
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (P1
VistaGen Therapeutics, Inc.
Social Anxiety Disorder (SAD)
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and
tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray
(fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18
through 65 with Social Anxiety Disorder induce1 expand
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PALISADE-4 and choose to enter the distinct open-label extension phase of the study. Type: Interventional Start Date: Sep 2024 |
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
Biohaven Therapeutics Ltd.
Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of BHV-7000 in
participants with Major Depressive Disorder (MDD) expand
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD) Type: Interventional Start Date: May 2024 |
Apimostinel + Automated Neurocognitive Training for Depression
Rebecca Price
Depression
Apimostinel shows initial promise as a novel rapid-acting antidepressant medication with
minimal side effects or safety concerns. Cognitive Training (CT) is a digital
intervention that has shown promise in extending the durability of another similar drug
(ketamine). This randomized controlled trial1 expand
Apimostinel shows initial promise as a novel rapid-acting antidepressant medication with minimal side effects or safety concerns. Cognitive Training (CT) is a digital intervention that has shown promise in extending the durability of another similar drug (ketamine). This randomized controlled trial will test the efficacy and safety of apimostinel (vs. placebo) for the acute treatment of depression, and will test the potential of CT to enhance and/or extend the durability of apimostinel's antidepressant effect. Type: Interventional Start Date: Oct 2024 |
A Text Messaging Intervention to Reduce Perinatal Depression Risk
University of Massachusetts, Worcester
Major Depressive Episode
Development and preliminary testing of a text messaging intervention that will reduce the
risk of a major depressive episode and worsening depressive symptoms in perinatal
individuals. The system will screen pregnant individuals, send tailored text messages
with links to enhanced content, and will1 expand
Development and preliminary testing of a text messaging intervention that will reduce the risk of a major depressive episode and worsening depressive symptoms in perinatal individuals. The system will screen pregnant individuals, send tailored text messages with links to enhanced content, and will include a peer chat function.This accessible text platform will leverage both the ease of use inherent in text messages and the power of enhanced content drawn evidence from based behavioral interventions (Interpersonal Therapy). Type: Interventional Start Date: Jul 2024 |
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Neumora Therapeutics, Inc.
Major Depressive Disorder
This is a 52-week open-label extension (OLE) study that will evaluate the safety,
tolerability, and effectiveness of NMRA-335140 in participants with major depressive
disorder (MDD). Participants who completed a parent study investigating the efficacy of
NMRA-335140 as a treatment for MDD (ie, NMRA1 expand
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this extension study. Type: Interventional Start Date: Nov 2023 |
Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With S1
VA Office of Research and Development
Schizophrenia
Bipolar Disorder
Depressive Disorder, Major
Stress Disorder, Post-Traumatic
Many individuals with serious mental illness have difficulty accurately interpreting
interpersonal cues and effectively engaging in social exchanges. Difficulties related to
the interpersonal aspects of work can lead to isolation, poor productivity, and job loss.
The goals of this study are to: 1)1 expand
Many individuals with serious mental illness have difficulty accurately interpreting interpersonal cues and effectively engaging in social exchanges. Difficulties related to the interpersonal aspects of work can lead to isolation, poor productivity, and job loss. The goals of this study are to: 1) adapt an evidence-based social cognitive skills intervention for work settings and use with Veterans, 2) examine the acceptability of the work focused skills training intervention, 3) assess the feasibility of combining the social cognitive skills training program with supported employment, and 4) examine change on functional outcomes. The current study will use feedback from veteran and employment specialist stakeholders to adapt an evidence-based social cognitive skills training program, Social Cognition and Interaction Training (SCIT). The intervention will be modified to tailor it to work relationships and to address any unique relationship concerns among Veterans that are identified by stakeholders. SCIT-Work Edition (SCIT-WE) will add: 1) education about work-related social norms; 2) examples of work-related social interactions that require perspective taking and problem- solving; 3) individual sessions with the study therapist to enhance learning and relevance to each participant's goals; 4) structured interactions with the participant's employment specialist to practice skills outside of group; and 5) skill application sessions with the participant's employment specialist that prompt use of skills after training is completed. SCIT-WE will be developed and piloted in an open trial with 20 Veterans enrolled in the supported employment program at the Minneapolis VA who have a qualifying serious mental illness diagnosis. SCIT-WE will be offered for 2 hours weekly over 13 weeks, when most participants are in the job development and job search phases of supported employment. While participating in the group skills training, participants will have weekly, individual homework review sessions with the group facilitator to promote understanding of the skills and to discuss relevance of the skills to personal goals. Participants also will practice skills weekly with their employment specialist for 10-15 minutes to promote use of skills outside of group sessions. In the 3-months following skills training completion, participants will complete 10 15-minute skills review sessions with their employment specialist to encourage continued skill application in a work setting. Participants will complete assessments at baseline, before receiving the intervention; 3-months post-enrollment, after participating in a weekly skills training group; and 6-months post-enrollment, after receiving 10 additional individual skills review sessions with their employment specialist. Accessibility will be measured with rate of treatment uptake, rate of treatment completion, and participant attitudes toward the intervention. Feasibility of the intervention will be assessed by examining retention in supported employment and the study at 3- and 6-months post-enrollment. Impact of the intervention will be examined with measures of quality of life, social adjustment, self-efficacy, and work relationship quality. It is hypothesized that the intervention will be acceptable to Veterans. The investigators predict a 50% treatment uptake rate, a 70% intervention completion rate, and positive ratings on measures of satisfaction, interest, and value. The investigators hypothesize that it will be feasible to complete this intervention in combination with supported employment activities. The investigators predict that retention in both skills training and supported employment will be 75% at 3-months post-enrollment and 60% 6-months post enrollment. The investigators hypothesize that positive change will be seen at 3-months post-enrollment and sustained at 6-months post-enrollment on measures of quality of life and social adjustment. The investigators predicted that self-efficacy regarding return to work will be improved at 3-months post-enrollment. The investigators predict that Veterans will report being productive and having positive work relationships 6-months post-enrollment. The findings will inform the development of a novel intervention targeting the social and functional impairments associated with serious mental illness. The knowledge gained from this study will guide the development of the next generation of interventions. Given that employment is a critical part of recovery, advancement in therapeutic interventions that support Veterans in this process will be of significance. Type: Interventional Start Date: Dec 2022 |
Comparing Telehealth to In-person a Combined Metacognitive Training in Veterans With mTBI/PTSD
VA Office of Research and Development
Brain Injury
Cognition
PTSD
Intervention
Veterans with mild traumatic brain injury (mTBI) and post-traumatic stress disorder
(PTSD) commonly experience cognitive impairments including attention and executive
function deficits that interfere with their ability to engage in productive personal and
social activities. Of the limited intervent1 expand
Veterans with mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) commonly experience cognitive impairments including attention and executive function deficits that interfere with their ability to engage in productive personal and social activities. Of the limited interventions available to address cognition, none rigorously train attention beyond strategy management. This study will evaluate an innovatively combined strategy training known as Goal Management Training plus computerized attention training in Veterans with mTBI/PTSD. Preliminary testing suggests an effectiveness in improving problem solving, attention and functional tasks in a small number of Veterans. Considering these promising results, cost effectiveness, and the demand for access to care from Veterans living in rural areas, a Randomized Controlled Trial will determine and compare the effects of this treatment, administered either in-person or via telehealth, on executive function, attention, other aspects of cognition and real life functional tasks. Type: Interventional Start Date: Nov 2022 |
Kind Minds Program for Youth with Anxiety and Depression
University of California, Los Angeles
Child Anxiety
Depression
Rates of anxiety and depression in youth are substantial, causing a major unmet need for
effective interventions. Participation in mindfulness interventions has been demonstrated
to reduce anxiety and depressive symptoms among teenagers. Parents' participation in
mindfulness interventions has also1 expand
Rates of anxiety and depression in youth are substantial, causing a major unmet need for effective interventions. Participation in mindfulness interventions has been demonstrated to reduce anxiety and depressive symptoms among teenagers. Parents' participation in mindfulness interventions has also been shown to reduce their children's mental health symptoms. However, there is no available evidence regarding potential additional benefits for adolescents' mental health of having both the adolescent and their parent or caregiver learn and practice mindfulness simultaneously. This pilot intervention study aims to explore potential additive effects of parent/caregiver participation in a digitally-based, kindness-focused, coached mindfulness intervention program for adolescents that lasts 9 weeks. Participating parent/caregiver-child pairs (n = 30) will include one teenager between 12 and 17 years old with a current diagnosis of an anxiety or depressive disorder and one parent/caregiver. All adolescent participants will take part in the mindfulness intervention. Half of the parents/caregivers will be randomized to also take part in the mindfulness program. Outcomes will be compared between families in which only the teen participates in the mindfulness program and families in which the teen and parent/caregiver participate in the intervention. Adolescents and parents/caregivers will take part in evaluations before, in the middle of, and after the end of the mindfulness program, meaning that participation in the study will take a total of approximately 12 weeks. Pre, mid, and post evaluations will include online questionnaires. Pre and post evaluations will also include clinical interviews via phone or video conference. Evaluations will include measures of mental health diagnoses and symptoms, mood, interpersonal and family functioning, mindfulness, and perceptions of/satisfaction with the program. Participating adolescents and parents/caregivers will also fill out weekly brief questionnaires of anxiety and depressive symptoms. The primary outcome of interest is adolescent mental health, including anxiety and depressive symptoms. Type: Interventional Start Date: May 2022 |
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic1
Yale University
PTSD
Alcohol Use Disorder
For this protocol, the investigators plan to collect pilot data to: 1. establish the
feasibility and safety of administering brexanolone to individuals with concurrent
Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD). expand
For this protocol, the investigators plan to collect pilot data to: 1. establish the feasibility and safety of administering brexanolone to individuals with concurrent Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD). Type: Interventional Start Date: Aug 2023 |
Ketamine for the Treatment of Depression in Parkinson's Disease
Yale University
Parkinson's Disease
Depression
The main purpose of this study is to examine the efficacy and safety of a repeated dosing
ketamine infusion paradigm compared to placebo in individuals with PD.
A subset of participants in each arm will undergo baseline and post-treatment PET and
fMRI scans, to examine whether changes in synaptic1 expand
The main purpose of this study is to examine the efficacy and safety of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD. A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD. Type: Interventional Start Date: Nov 2021 |
Natural History of Depression, Bipolar Disorder and Suicide Risk
National Institute of Mental Health (NIMH)
Behavioral Symptoms
Suicide
Self-Injurious Behavior
Sensory System Agents
Analgesics
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One
reason is that there are no objective ways to measure how these disorders affect the body
and respond to different treatments. In this study, researchers want to perform tests on
people undergoing clinical care for1 expand
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medications will improve thoughts of suicide. People 18 years or older who are receiving treatment for depression, bipolar disorder, or suicide risk may take part in this study. Participants must have also been enrolled in protocol 01-M-0254. This study will be conducted at the NIH Clinical Center in Bethesda, MD. The study typically lasts up to 12 weeks, but may last longer if a participant s treatment continues past that time. Participants will have weekly interviews and questionnaires while they are being treated for their mood disorder. Other tests are optional and include psychological testing, blood draws, sleep tests, and imaging scans. These will be done at the start and the end of research participation.... Type: Observational Start Date: Sep 2024 |
Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)
National Institute of Mental Health (NIMH)
Unipolar Depression
Background:
Electroconvulsive therapy (ECT) is used to treat people with severe depression. During
ECT, the brain is given electric pulses that cause a seizure. Although it is effective,
it can cause side effects, including memory loss. Researchers want to study a new way to
give ECT called iLAST.1 expand
Background: Electroconvulsive therapy (ECT) is used to treat people with severe depression. During ECT, the brain is given electric pulses that cause a seizure. Although it is effective, it can cause side effects, including memory loss. Researchers want to study a new way to give ECT called iLAST. Objective: To see if iLAST is safe and feasible in treating depression. Eligibility: People ages 22 70 years old who have major depressive disorder and are eligible for ECT Design: Participants will be screened under protocol 01-M-0254. This includes: Medical and psychiatric history and exam Blood and urine tests Participants will be inpatients at the Clinical Center. They study has 3 phases and will last up to 20 weeks. Phase I will last 1 week. It includes: MRI: Participants will lie in a scanner that takes pictures of the body MEG: A cone over the participant s head will record brain activity. TMS: A wire coil placed on the participant s scalp will produce an electrical current to affect brain activity. SEP: An electrode on the participant s wrist will give a small electrical shock to test nerve function. Phase II will last 2 and a half weeks. It includes: Seven sessions of iLAST under general anesthesia. Participants may also get standard ECT. EEG: A small electrode placed on the participant s scalp will record brain waves. Interviews about mood, symptoms, and side effects. Participants facial expressions may be video recorded. TMS Phase III will last at least 1 week. It will include: MRI EEG TMS MEG Standard ECT if needed. Participants will have sessions every other day, 3 times a week. Sponsoring Institution: National Institute of Mental Health ... Type: Interventional Start Date: Nov 2024 |
Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers
National Institute of Mental Health (NIMH)
Mood Disorders
Anxiety Disorders
Healthy Volunteers
Bipolar Disorder
Depression
The purpose of this protocol is to allow for the careful screening of patients and
healthy volunteers for participation in research protocols in the Experimental
Therapeutics and Pathophysiology Lab (ETPB) at the National Institute of Mental Health
(NIMH) and for the collection of natural history d1 expand
The purpose of this protocol is to allow for the careful screening of patients and healthy volunteers for participation in research protocols in the Experimental Therapeutics and Pathophysiology Lab (ETPB) at the National Institute of Mental Health (NIMH) and for the collection of natural history data. In addition the protocol will allow clinicians to gain more experience in the use of a variety of polysomnographic and high-density EEG recordings. Subjects in this protocol will undergo an evaluation which may include: a psychiatric interview; a diagnostic interview; rating scales; a medical history; a physical exam; brain magnetic resonance imaging (MRI); electroencephalography (EEG); electrocardiography (EKG), magnetoencephalography (MEG); blood, saliva and urine laboratory evaluation; and a request for medical records. Subjects may also be asked to complete questionnaires about attitudes towards research and motivation for research participation. The data collected may also be linked with data from other mood and anxiety disorder protocols (e.g., brain imaging, DNA, psychophysiology tests, treatment studies, etc) for the purposes of better understanding the diagnosis, pathophysiology, and treatment response of patients with mood disorders. Parents of minors will be interviewed. Upon conclusion of the screening process, subjects will either be offered participation in a research protocol and will sign the appropriate informed consent, or will be considered not appropriate for participation in research and will be referred back into the community. The current protocol thus serves as an entry point for individuals with mood or anxiety disorders or healthy volunteers to enter NIMH IRB approved ETPB protocols.... Type: Observational Start Date: Feb 2001 |
Greater Houston Area Pediatric Bipolar Registry
The University of Texas Health Science Center, Houston
Pediatric Bipolar Disorder
The purpose of this study is to perform a comprehensive research assessment of children
and adolescents who meet The Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition (DSM-V) criteria for Bipolar Disorder (BD) , offspring of a parent with BD, and
healthy controls (HC), to obtain1 expand
The purpose of this study is to perform a comprehensive research assessment of children and adolescents who meet The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for Bipolar Disorder (BD) , offspring of a parent with BD, and healthy controls (HC), to obtain blood samples and saliva samples from each subject to allow the evaluation for BD biomarkers and genetic information, to notify participants about future research studies they may qualify for , to recommend follow-up with an outpatient provider if needed and to use magnetic resonance imaging (MRI) (structural MRI and diffusion tensor imaging) to investigate brain structures and relevant pathways associated with mood and behavioral regulation, conversion from softer forms of the BD spectrum (BD-NOS) to harder forms (BD-I and BD-II) and possible early identification. Type: Observational [Patient Registry] Start Date: Dec 2022 |
BHV-7000 Acute Treatment of Bipolar Mania
Biohaven Therapeutics Ltd.
Bipolar Disorder
The purpose of this study is to determine whether BHV-7000 is a safe and effective acute
treatment for manic episodes in bipolar disorder I. expand
The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I. Type: Interventional Start Date: May 2024 |
Psilocybin in Chronic Low Back Pain and Depression
Johns Hopkins University
Chronic Low-back Pain
Depression
This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain
among patients with co-morbid chronic low back pain and depression (CLBP+D).
Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or
methylphenidate (40mg absolute dose). Par1 expand
This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose). Participants will be asked to complete assessments of pain, depressive symptoms, and more general questionnaires regarding the participants experiences during the experimental sessions and the associated enduring effects. Type: Interventional Start Date: Apr 2024 |
A Study of CLE-100 (oral Esketamine) As an Adjunctive Treatment to Standard Antidepressants for Maj1
Clexio Biosciences Ltd.
Adjunctive Treatment of Major Depressive Disorder (MDD)
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major
Depressive Disorder (MDD) participants with an inadequate response to standard
antidepressants The objective of the study is to assess CLE-100 (oral esketamine) for the
treatment of MDD in participants currently tre1 expand
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100 (oral esketamine) for the treatment of MDD in participants currently treated with an oral antidepressant medication and who have an inadequate response to at least 2 antidepressants. Type: Interventional Start Date: Mar 2024 |
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Me1
Boehringer Ingelheim
Depressive Disorder, Major
This study is open to adults between 18 and 65 with a type of depression (major
depressive disorder) for whom previous treatments for depression did not work. The
purpose of the study is to find out whether a medicine called BI 1569912 helps people
with depression.
Participants continue their stan1 expand
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants continue their standard therapy throughout the study. Participants are put into 4 groups by chance. 3 of the 4 groups take different doses of BI 1569912. 1 group takes placebo. Placebo tablets looks like BI 1569912 but do not contain any medicine. Participants take the tablets once a day for 6 weeks. Participants are in the study for about 2 to 4 and a half months. During this time, they visit the study site at least 6 times. At the visits, doctors ask participants about their symptoms. The participants answer questions about their depression symptoms. The results are compared between the groups. The doctors also regularly check the general health of participants. Type: Interventional Start Date: Mar 2024 |
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Sharmin Ghaznavi
Major Depressive Disorder
This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the
effects of a single dose of psilocybin on rumination and the neural correlates of
rumination in individuals with major depressive disorder. expand
This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder. Type: Interventional Start Date: Oct 2024 |
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
M.D. Anderson Cancer Center
Depression, Anxiety
Psilocybin-Assisted Psychotherapy
Advanced Cancer
To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy
on depression and/or anxiety in participants who are being treated for advanced cancer. expand
To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer. Type: Interventional Start Date: Apr 2024 |
Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD
VA Office of Research and Development
Post-Traumatic Stress Disorder (PTSD)
Leveraging veterans' intimate relationships during treatment for posttraumatic stress
disorder (PTSD) has the potential to concurrently improve PTSD symptoms and relationship
quality. Brief Cognitive-Behavioral Conjoint Therapy (bCBCT) is a manualized treatment
designed to simultaneously improve PT1 expand
Leveraging veterans' intimate relationships during treatment for posttraumatic stress disorder (PTSD) has the potential to concurrently improve PTSD symptoms and relationship quality. Brief Cognitive-Behavioral Conjoint Therapy (bCBCT) is a manualized treatment designed to simultaneously improve PTSD and relationship functioning for couples in which one partner has PTSD. Although efficacious in improving PTSD, the effects of CBCT on relationship satisfaction are small, especially among Veterans. Pharmacological augmentation of bCBCT with intranasal oxytocin, a neurohormone that influences mechanisms of trauma recovery and social behavior, may help improve the efficacy of bCBCT. The purpose of this randomized placebo-controlled trial is to compare the clinical and functional outcomes of bCBCT augmented with intranasal oxytocin (bCBCT + OT) versus bCBCT plus placebo (bCBCT + PL). The investigators will also explore potential mechanisms of action: communication, empathy, and trust. Type: Interventional Start Date: Oct 2024 |
A Study of Spoken Language in Mania
Mayo Clinic
Manic Episode
Bipolar I Disorder
This research is being done to find if there are changes with voice and speech during
episodes of mania. expand
This research is being done to find if there are changes with voice and speech during episodes of mania. Type: Interventional Start Date: Apr 2023 |
- Previous
- Next